Large-scale testing (Phase 3)Ended earlyNCT05022329What this trial is testingCOVID-19 Vaccine Boosters in Patients With CKDWho this might be right forChronic Kidney DiseasesCOVID-19 Sunnybrook Health Sciences Centre 273
Testing effectiveness (Phase 2)Study completedNCT05142553What this trial is testingImmunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.Who this might be right forCOVID-19SARS-CoV-2 Acute Respiratory Disease Hipra Scientific, S.L.U 887
Testing effectiveness (Phase 2)Study completedNCT05770180What this trial is testingPhase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)Who this might be right forCOVID-19 WestVac Biopharma Co., Ltd. 450
Post-approval studies (Phase 4)UnknownNCT05104437What this trial is testingEvaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or DiabetesWho this might be right forCOVID-19 Pneumonia China National Biotec Group Company Limited 1,440
Early research (Phase 1)UnknownNCT06167915What this trial is testingSafety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster VaccinationWho this might be right forSARS-CoV-2COVID-19 Vaccine Guangzhou Patronus Biotech Co., Ltd. 120
Large-scale testing (Phase 3)Looking for participantsNCT05415267What this trial is testingImmunosuppression and COVID-19 BoostersWho this might be right forCOVID-19 Kirby Institute 320
Testing effectiveness (Phase 2)Ended earlyNCT05000216What this trial is testingCOVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersWho this might be right forRheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Pemphigus Vulgaris+6 more National Institute of Allergy and Infectious Diseases (NIAID) 258
Early research (Phase 1)Active Not RecruitingNCT05389319What this trial is testingAssess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy AdultsWho this might be right forCOVID-19 University Hospital Tuebingen 96
Not applicableStudy completedNCT04794387What this trial is testingThe Lymphoma and Leukemia Society Amended COVID-19 RegistryWho this might be right forCovid19 Blood Cancer United 1,000
Not applicableStudy completedNCT05808413What this trial is testingExploring the Effect of Video Interventions on Intentions for Continued COVID-19 VaccinationWho this might be right forVaccine RefusalCOVID-19 Sir Mortimer B. Davis - Jewish General Hospital 3,567
Large-scale testing (Phase 3)UnknownNCT05279365What this trial is testingPROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALSWho this might be right forSARS CoV 2 InfectionCOVID-19 DHR Health Institute for Research and Development 1,000
Large-scale testing (Phase 3)Study completedNCT06181292What this trial is testingSafety and Immunogenicity of a Booster Vaccination With an Adapted VaccineWho this might be right forSARS-CoV2 Infection Hipra Scientific, S.L.U 913
Very early researchUnknownNCT06272253What this trial is testingUNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent SubjectsWho this might be right forCOVID-19 PandemicCOVID-19 Vaccines Dr. Soetomo General Hospital 250
Large-scale testing (Phase 3)Ended earlyNCT05683600What this trial is testingEfficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or OlderWho this might be right forCOVID-19 Guangzhou Patronus Biotech Co., Ltd. 3,000
Testing effectiveness (Phase 2)UnknownNCT05873374What this trial is testingEvaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19Who this might be right forCOVID-19 VaccineCOVID-19 Baiya Phytopharm Co., Ltd. 75
Testing effectiveness (Phase 2)Looking for participantsNCT06255626What this trial is testingSafety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.Who this might be right forCOVID-19 ANRS, Emerging Infectious Diseases 215
Testing effectiveness (Phase 2)Study completedNCT04979949What this trial is testingBooster Vaccination Against COVID-19Who this might be right forCOVID-19Sars-CoV-2 Infection Health Institutes of Turkey 222
Early research (Phase 1)WithdrawnNCT05366296What this trial is testingSafety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA VaccineWho this might be right forCOVID-19 Pandemic Wuhan Recogen Biotechnology Co., Ltd.
Post-approval studies (Phase 4)Study completedNCT05343871What this trial is testingImmunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing TrialWho this might be right forCOVID-19 Albert B. Sabin Vaccine Institute 2,354
Very early researchUnknownNCT05585567What this trial is testingA Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5Who this might be right forCOVID-19 Pandemic Livzon Pharmaceutical Group Inc. 48